Patterns of Amphotericin B Killing Kinetics against Seven Candida Species
- 1 July 2004
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (7) , 2477-82
- https://doi.org/10.1128/aac.48.7.2477-2482.2004
Abstract
In a previous study tolerance to amphotericin B (AMB) was found among Candida parapsilosis and C. dubliniensis strains by seeding the whole volumes of wells used for MIC determinations, and minimum fungicidal concentrations (MFC) for non- C. albicans Candida strains were demonstrated to be above the levels safely achievable in serum. As an extension of that study, we performed time-kill assays with 26 blood culture isolates (6 C. albicans , 5 C. parapsilosis , 5 C. krusei , 4 C. glabrata , 3 C. lusitaniae , and 3 C. tropicalis isolates), 3 oropharyngeal C. dubliniensis isolates, 3 AMB-susceptible isolates (ATCC 90028, ATCC 22019, ATCC 6254), and 6 AMB-resistant isolates (ATCC 200955, ATCC 200956, ATCC 200950, ATCC 200951, ATCC 200952, ATCC 200953) using RPMI 1640 medium and 0.12 to 32 μg of AMB per ml and determined the numbers of CFU per milliliter at 0, 2, 4, 8, 12, 24, and 48 h. MFCs and time-kill patterns were species specific (MFCs, ≤1 μg/ml for all C. dubliniensis and C. albicans isolates except AMB-resistant strain ATCC 200955; MFCs, 2 to >16 μg/ml for the other isolates). The times required to reach the fungicidal endpoint (99.9% killing) at four times the MIC were 2 h for C. albicans and C. dubliniensis , 16 h for C. glabrata , 24 h for C. parapsilosis and C. lusitaniae , and ≥40 h for C. tropicalis and C. krusei . The killing rate increased as the AMB concentration was increased up to 2 μg/ml. The highest killing rates were achieved for C. albicans , C. dubliniensis , and C. lusitaniae , while viable C. tropicalis, C. krusei , and C. parapsilosis cells were present after 48 h (MICs, ≤2 μg/ml) when AMB was used at 2 μg/ml. Time-kill curves and MFCs can detect viable cells after 48 h when AMB is used at ≥2 μg/ml. The failure of AMB treatment could be due to its poor killing activity against some species at the concentrations reached in patients' serum.Keywords
This publication has 29 references indexed in Scilit:
- In Vitro Activities of Voriconazole, Posaconazole, and Four Licensed Systemic Antifungal Agents against Candida Species Infrequently Isolated from BloodJournal of Clinical Microbiology, 2003
- Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997–2000International Journal of Antimicrobial Agents, 2002
- Rates and Extents of Antifungal Activities of Amphotericin B, Flucytosine, Fluconazole, and Voriconazole against Candida lusitaniae Determined by Microdilution, Etest, and Time-Kill MethodsAntimicrobial Agents and Chemotherapy, 2002
- Influence of Human Serum on Antifungal Pharmacodynamics with Candida albicansAntimicrobial Agents and Chemotherapy, 2001
- In Vitro Activities of Terbinafine against Aspergillus Species in Comparison with Those of Itraconazole and Amphotericin BAntimicrobial Agents and Chemotherapy, 2001
- Do In Vitro Susceptibility Data Predict the Microbiologic Response to Amphotericin B? Results of a Prospective Study of Patients withCandidaFungemiaThe Journal of Infectious Diseases, 1998
- Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniaeDiagnostic Microbiology and Infectious Disease, 1994
- Candida parapsilosis: Epidemiology, Pathogenicity, Clinical Manifestations, and Antimicrobial SusceptibilityClinical Infectious Diseases, 1992
- Amphotericin B-resistant yeast infection in severely immunocompromised patientsThe American Journal of Medicine, 1988
- Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte functionThe Lancet Healthy Longevity, 1978